| Cataract removal is the most commonly performed operation in patients over 65 years of age. Phacoemulsification with intraocular lens implantation has the advantages of small incisions, low astigmatism, and so on. With the extensive application of this technique, the control of intra-ocular inflammation following cataract surgery has been an attention by the ocular surgeons increasingly.Surgical trauma elicits a cascade of ocular inflammatory reactions in eyes undergoing cataract surgery, Bad control of this inflammation is related to the postoperative complications such as corneal edema, intraocular pressure spike, cystoid macular edema, and posterior capsule opacification. Topical corticosteroids are used for the prevention of the postoperative inflammation widely, although, they have superior anti-inflammatory effects, they are also responsible for a greater range of adverse events, such as increasing intra-ocular pressure, more presence of postoperative ocular infection. Recently, many medications with low side effects have been applied in the treatment of postoperative inflammation following cataract extraction, many of them are nonsteroidal anti-inflammatory drugs.Pranopulin 0.1% eyedrops is an ophthalmic formulation of pranoprofen, a topical nonsteroid, which is developed by Yoshitomi Pharmaceutical Industries, Ltd, it has thefunction of preventing the synthesis of prostaglandins and stabilizing the cell's membrane. The lab researches demonstrate an effective anti-inflammatory action, and good inhibit of prostaglandin-induced aqueous flare elevation. Clinical researches indicate that it is effective on the control of intra-ocular inflammation following cataract surgery, and combining with corticosteroid is more effective in suppressing inflammation.[Purpose]Through comparing the efficacy of pranoprofen 0.1% eyedrops, fluorometholone 0.1% eyedrops and their combination in the control of the inflammation after phacoemulsification followed by intraocular lens implantation, to give clinical evidence and to find a better solution on the clinical pharmacologic strategies of the postoperative inflammatory.[Patients and Methods]One hundred and forty-one consecutive senile cataract subjects (141 eyes) were enrolled in a prospective, investigator-masked, randomized controlled trial, 58 male and 83 female, The mean patient age was 69.59years 6.72 (SD) ,range 52 to 82 years. Excluding subjects with systemic inflammatory or ocular infection; excluding glaucoma, uveitis, traumatic cataract, and other diseases that will cause sever inflammatory after cataract surgery.Patients were randomly assigned to three groups; pranoprofen 1% eyedrops group (47 subjects), fluorometholone 0.1% eyedrops group (47 subjects) and combined group (47 subjects).All operations were performed by the same surgeon under topical anesthesia and posterior chamber IOL was placed in the capsular bag. In all cases, the same balanced salt solution (BSS) and viscoelastics were used during the surgery.Postoperatively, patients used topical pranoprofen or fluorometholone drops six times a day for the first one week, four times a day for the following three weeks; and in the combined group patients used topical pranoprofen and fluorometholone drops bothfour times a day for the first one week, both three times a day for the folio whig three weeks. Patients received postoperative topical antibiotic prophylaxis with ofloxacin 0.3% (Tarividåº), one drop three tunes daily given 10 min after the topical steroid or nonsteroid for two weeks.Patients were examined at the first postoperative day (day 1), and days 7 and 30. Postoperative evaluations included patient history regarding any ocular discomfort, visual acuity, slit-lamp and fundus examinations, IOP measurement. The major efficacy parameters assessed clinically on each visit were anterior chamber flare and conjunctival hyperemia. All evaluations were performed by one same surgeon. Laser flare cell meter FC-2000(Kowa) was employed for examination of anterior chamber... |